- Coordinator
- Tetrakit Technologies Aps, Denmark
- Runs
- 1 July 2025 to 30 June 2027
- Status
- Running
- EU funding
- €2.5m
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 101218021
What the project is doing
In the project's own words, from its summary on CORDIS.
TetraKit Technologies (TT) is developing the TetraKit Platform, a universal radiolabelling platform that enables the synthesis of novel therapeutic and diagnostic (theranostic) radiopharmaceuticals (RPs). By overcoming the limitations of currently available radiochemistry solutions, TT will address the unmet need for an innovative approach that makes radiolabeling, specifically with radiohalogens, simple, rapid, effective and scalable.
Based on an ultrafast next generation tetrazine ligation and linker technology, the TetraKit Platform allows labelling of any biomolecule (target vector) with any radiohalogen or radiometal, according to a versatile ‘plug-and-play’ principle. As such, TT will facilitate unleashing the full potential of novel theranostic RPs to serve the need of millions of cancer patients worldwide. To validate the TetraKit Platform, TT seeks EIC Accelerator blended financing to advance the clinical development of the lead asset emerging from the platform, 131I-DualFAPi, an iodine-131-labelled therapeutic RP that targets the fibroblast activation protein (FAP) – THE ‘next billion-dollars theranostics target’.
Initially to be developed for the treatment of metastasized Triple Negative Breast Cancer (TNBC), an aggressive type of cancer with poor survival chances, TT’s lead asset will be the first radiohalogenated FAP-targeting therapeutic RP in clinical development, made possible by the TetraKit Platform. Completion of a Phase 1/2 program in TNBC patients will present a significant value inflection point for TT, which is anticipated to result in a strategic partnership for the final development and commercialization steps.
Successful development of 131I-DualFAPi will be an essential milestone that will allow TT to fully exploit the TetraKit Platform, bringing immense commercial and societal value.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Tetrakit Technologies Aps | Kobenhavn | Denmark | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI